Invernizzi R, Bertolino G, Girino M, Perseghin P, Michienzi M, Nano R
Blut. 1985 May;50(5):277-85. doi: 10.1007/BF00319753.
Cytochemical methods were used to determine the distribution of dipeptidylaminopeptidase IV (DAP IV) and II (DAP II) in lymphoid cell populations from patients with lymphoproliferative diseases. Special attention was paid to unusual intracellular distribution patterns which might correlate with the presence of various membrane markers. In healthy patients, about 50% of the circulating lymphocytes were found to be positive to both reactions, the intracellular distribution patterns being variable. The DAP IV reaction was negative in all B-CLL cases. In 2 cases of T-CLL with phenotype E+ OKT3+T4-T8+ one was negative and one was weakly positive, while two cases of T-CLL with phenotype E+ OKT3+T4+T8- were both strongly positive. The other non-T lymphoproliferative diseases studied were negative for DAP IV, while one T-ALL and three T-lymphoma cases showed a strong granular or diffuse distribution. The DAP II reaction was strongly positive in all the T lymphoproliferative diseases studied, irrespective of their immunological phenotype. This reaction was also weakly positive in some cases of plasmocytoma and lymphoplasmacytoid lymphoma.
采用细胞化学方法测定淋巴增生性疾病患者淋巴样细胞群体中二肽基氨基肽酶IV(DAP IV)和二肽基氨基肽酶II(DAP II)的分布。特别关注了可能与各种膜标志物存在相关的异常细胞内分布模式。在健康患者中,约50%的循环淋巴细胞对两种反应均呈阳性,细胞内分布模式各不相同。在所有B细胞慢性淋巴细胞白血病(B-CLL)病例中,DAP IV反应均为阴性。在2例表型为E+OKT3+T4-T8+的T细胞慢性淋巴细胞白血病(T-CLL)病例中,1例为阴性,1例为弱阳性,而2例表型为E+OKT3+T4+T8-的T-CLL病例均为强阳性。所研究的其他非T细胞淋巴增生性疾病的DAP IV均为阴性,而1例T细胞急性淋巴细胞白血病(T-ALL)和3例T细胞淋巴瘤病例表现为强颗粒状或弥漫性分布。在所研究的所有T细胞淋巴增生性疾病中,无论其免疫表型如何,DAP II反应均为强阳性。在一些浆细胞瘤和淋巴浆细胞样淋巴瘤病例中,该反应也呈弱阳性。